$LKFT Income Statement | Understand Stock

$LKFT

$31.82 +$0.14 (0.43%) Close

Financial Statements

In millions of EUR; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Product net sales
Supply revenues
Collaboration revenues
Total net revenues
Cost of sales
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Impairment of the cell therapy business
Other operating income
Operating loss
Fair value re-measurement of share subscription agreement and warrants
Fair value adjustments and net exchange differences
Other financial income
Other financial expenses
Profit / (Loss) (-) before tax
Income taxes
Net loss from continuing operations
Net profit/(loss) (-) from discontinued operations, net of tax
Net profit / (loss) (-)
Net loss attributable to:
Owners of the parent
Basic earnings per share (in EUR per share)
Diluted earnings per share (in EUR per share).
Basic and diluted loss per share from continuing operations (in EUR per share)
Basic and Diluted loss per share from continuing operations (in EUR per share).
Weighted average number of shares - Basic (in '000 shares)
Weighted average number of shares - Diluted (in '000 shares)

Comments